Search results
Genentech’s Phase III STARGLO Study Demonstrates Columvi... With Relapsed or Refractory Diffuse...
Morningstar· 4 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell ...
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 2 days agoFollicular lymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma
Campaign fuels efforts to find better treatments for blood cancers in children
NBC Dallas Fort Worth· 13 hours agoLeukemia and Lymphoma Society's (LLS) Dare to Dream project hopes to raise money for research of...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe trial results suggest that this Calquence combination therapy could...shows potential to extend...
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? - Nurix Therapeutics...
Benzinga· 2 days agos JNJ Imbruvica (Ibrutinib), and AstraZeneca Plc’s AZN Calquence (Acalabrutinib). NX-5948 is being...
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 9.7% in May
ETF DAILY NEWS· 4 hours agoCaribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 11,510,000 ...
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks· 1 day agoFree Report) reported updated results from a cohort of an ongoing phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (WM), a rare form ...
Lantern Pharma secures Japan patent for cancer drug By Investing.com
Investing.com· 7 days agoThe Japan Patent Office issued the certificate for the molecule, which is currently in a Phase 1...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with...
Benzinga· 3 days agoDr. Kim Linton, M.B.Ch.B, MRCP, Ph.D., FRCP, senior lecturer at the...
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $14.20
ETF DAILY NEWS· 5 days agoAdicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports ...